Raffaella Greco

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 178 publications

Predicting Relapse After Autologous Hematopoietic Cell Transplantation in Systemic Sclerosis: What Autoantibodies Can and Cannot Tell Us.

Predicting Relapse After Autologous Hematopoietic Cell Transplantation in Systemic Sclerosis: What Autoantibodies Can and Cannot Tell Us.

Journal: The Journal of rheumatology
Published: July 01, 2026

Baseline liver stiffness predicts SOS/VOD after allogeneic hematopoietic stem cell transplantation.

Baseline liver stiffness predicts SOS/VOD after allogeneic hematopoietic stem cell transplantation.

Journal: Bone marrow transplantation
Published: June 19, 2026

Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee.

Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee.

Journal: Bone marrow transplantation
Published: June 08, 2026

Antibacterial prophylaxis and antimicrobial stewardship in the era of innovative therapies for haematological malignancies: transplantation, cellular therapies and new drugs.

Antibacterial prophylaxis and antimicrobial stewardship in the era of innovative therapies for haematological malignancies: transplantation, cellular therapies and new drugs.

Journal: JAC-antimicrobial resistance
Published: April 10, 2026

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

Journal: Bone marrow transplantation
Published: March 27, 2026

Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT.

Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT.

Journal: Frontiers in immunology
Published: February 28, 2026

The conditional benefit of being alive and disease free at 2 years after transplant: a long term survival evaluation among 456 patients affected by acute myeloid leukemia.

The conditional benefit of being alive and disease free at 2 years after transplant: a long term survival evaluation among 456 patients affected by acute myeloid leukemia.

Journal: Frontiers in immunology
Published: February 26, 2026

Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties.

Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties.

Journal: Bone marrow transplantation
Published: January 21, 2026

Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).

Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).

Journal: Bone marrow transplantation
Published: December 10, 2025

Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective study.

Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective study.

Journal: Bone marrow transplantation
Published: October 31, 2025

Long-term remission of neuromyelitis optica with allogeneic hematopoietic stem cell transplant.

Long-term remission of neuromyelitis optica with allogeneic hematopoietic stem cell transplant.

Journal: Med (New York, N.Y.)
Published: October 30, 2025

Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.

Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.

Journal: British journal of haematology
Published: October 02, 2025
Showing 1-12 of 178

Last Updated: 09/26/2026